Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Axitinib (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Pharmacodynamics
- 02 Jun 2015 Results assessing pharmacodynamic presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 14 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 29 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 reported by ClinicalTrials.gov.